Andrew Hersh, MD
Pulmonary Disease · Montrose, CONPI 1285924480
Payments from drug & device makers
Across 48 payments — averaging $98.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$2K
- Noah Medical Corporation$1K
- Medtronic$761
- GSK$155
- Johnson & Johnson$151
- Sanofi-aventis U.S. LLC$100
- plus $314 from 10 others
What the payments were for
- Travel & lodging$2,89461%
- Food & beverage$1,72837%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 7 | $2,190 |
| Noah Medical Corporation | 7 | $1,052 |
| Medtronic | 8 | $761 |
| GSK | 7 | $155 |
| Johnson & Johnson(2 entities) | 2 | $151 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| AstraZeneca | 4 | $72 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $40 |
| Boehringer Ingelheim | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Sanofi | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Insmed, Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $19 |
| Genentech USA, Inc. | 2 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$1,987
- PULMONX CHARTIS TABLET CONSOLE$1,987
- CHARTIS CATHETER$1,987
- ZEPHYR DELIVERY CATHETER$1,987
- GALAXY$881
- Signia$471
- MATRIXNEURO$139
- SYNTHECEL$139
- TRUMATCH$139
How this compares
$4,722 in reported general payments places this provider in the 65th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 18 | $67,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $48,860 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $41,782 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,750 |
| Spiriva RespimatTiotropium Bromide | 12 | $12,550 |
| Varenicline Tartrate | 51 | $10,778 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,584 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $7,025 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,222 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,241 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,200 |
| Gabapentin | 35 | $628 |
| Prednisone | 55 | $245 |
| Azithromycin | 16 | $222 |
| Montelukast Sodium | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta | $155 | $129,052100 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $33 | $54,33268 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $72 | $20,97346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Montrose
- Heather HoweMontrose$52K
- David SchwartzAurora$6.7M
- Michael WechslerDenver$3.6M
- David BadeschAurora$2.2M
- Jennifer Taylor CousarDenver$1.4M
- Evans Fernandez PerezDenver$1.3M
- Ronald BalkissoonDenver$1.2M
- Jeffrey SwigrisDenver$845K
- Joshua SolomonDenver$705K
- Thomas WilcoxBoulder$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.